We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CIP NINTEDANIB (Cipla Australia Pty Ltd)
Product name
CIP NINTEDANIB
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
148 (255 working days)
Active ingredients
nintedanib esilate
Registration type
New generic medicine
Indication
TRADE NAME is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after failure of first line chemotherapy. IPF, other chronic fibrosing ILDs with a progressive phenotype, and SSc-ILD